| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
867,229 |
| 52
Week Range: |
$187.64 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
19,405 |
57,754 |
513,978 |
| Total Sell Value |
$0 |
$4,136,219 |
$11,851,618 |
$91,955,621 |
| Total People Sold |
0 |
2 |
7 |
9 |
| Total Sell Transactions |
0 |
2 |
21 |
74 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gryska David W |
Director |
– • – |
2022-01-14 |
4 |
AS |
$135.24 |
$608,581 |
D/D |
(4,500) |
46,250 |
|
-0% |
|
| Gryska David W |
Director |
– • – |
2022-01-14 |
4 |
OE |
$20.06 |
$90,270 |
D/D |
4,500 |
50,750 |
|
- |
|
| Siegall Clay B |
President & CEO |
• • – |
2022-01-07 |
4 |
AS |
$143.91 |
$2,466,743 |
D/D |
(17,044) |
667,945 |
|
-1% |
|
| Siegall Clay B |
President & CEO |
• • – |
2022-01-07 |
4 |
OE |
$26.10 |
$444,848 |
D/D |
17,044 |
676,108 |
|
- |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2022-01-03 |
4 |
AS |
$152.58 |
$1,323,648 |
D/D |
(8,675) |
79,686 |
|
-19% |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2021-12-21 |
4 |
AS |
$155.58 |
$43,562 |
D/D |
(280) |
88,361 |
|
-17% |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2021-12-20 |
4 |
AS |
$149.85 |
$198,252 |
D/D |
(1,323) |
49,973 |
|
-17% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2021-12-20 |
4 |
AS |
$149.85 |
$51,698 |
D/D |
(345) |
59,500 |
|
-17% |
|
| Liu Jean I |
Chief Legal Officer |
• – – |
2021-12-20 |
4 |
AS |
$149.85 |
$41,359 |
D/D |
(276) |
70,432 |
|
-17% |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2021-12-20 |
4 |
AS |
$149.85 |
$41,958 |
D/D |
(280) |
88,641 |
|
-17% |
|
| Siegall Clay B |
President & CEO |
• • – |
2021-12-20 |
4 |
AS |
$149.85 |
$183,866 |
D/D |
(1,227) |
667,945 |
|
-17% |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2021-12-20 |
4 |
AS |
$149.85 |
$51,698 |
D/D |
(345) |
128,458 |
|
-17% |
|
| Siegall Clay B |
President & CEO |
• • – |
2021-12-07 |
4 |
AS |
$146.54 |
$6,756,632 |
D/D |
(45,449) |
669,172 |
|
-1% |
|
| Siegall Clay B |
President & CEO |
• • – |
2021-12-07 |
4 |
OE |
$26.10 |
$1,186,219 |
D/D |
45,449 |
674,520 |
|
- |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2021-11-11 |
4 |
AS |
$177.94 |
$1,071,774 |
D/D |
(6,000) |
59,845 |
|
-22% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2021-11-11 |
4 |
OE |
$26.10 |
$156,600 |
D/D |
6,000 |
65,845 |
|
- |
|
| Liu Jean I |
GC/EVP, Leg Affairs |
• – – |
2021-11-04 |
4 |
OE |
$46.37 |
$74,980 |
D/D |
1,617 |
70,708 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2021-11-04 |
4 |
OE |
$46.37 |
$99,974 |
D/D |
2,156 |
128,803 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2021-11-03 |
4 |
AS |
$185.00 |
$7,442,920 |
D/D |
(40,232) |
126,647 |
|
-23% |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2021-11-03 |
4 |
OE |
$44.09 |
$1,773,829 |
D/D |
40,232 |
166,879 |
|
- |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2021-11-01 |
4 |
OE |
$46.37 |
$99,974 |
D/D |
2,156 |
59,845 |
|
- |
|
| Liu Jean I |
GC/EVP, Leg Afairs |
• – – |
2021-11-01 |
4 |
AS |
$173.00 |
$6,187,369 |
D/D |
(34,876) |
69,091 |
|
-23% |
|
| Liu Jean I |
GC/EVP, Leg Afairs |
• – – |
2021-11-01 |
4 |
OE |
$35.95 |
$1,253,792 |
D/D |
34,876 |
103,967 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2021-10-29 |
4 |
AS |
$180.00 |
$6,041,523 |
D/D |
(33,564) |
126,647 |
|
-22% |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2021-10-29 |
4 |
OE |
$41.04 |
$1,377,467 |
D/D |
33,564 |
160,211 |
|
- |
|
1805 Records found
|
|
Page 9 of 73 |
|
|
